Pembrolizumab vs Trastuzumab
Pembrolizumab vs Trastuzumab: Overview
This comparison examines the pharmacological differences between Pembrolizumab and Trastuzumab.
Mechanism of Action
Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.
Trastuzumab: Anti-HER2 monoclonal antibody inhibiting receptor signaling.
Pharmacokinetics
Half-life: Pembrolizumab — 26 days; Trastuzumab — 28 days.
Chemical Properties
Type: Pembrolizumab — Antibody; Trastuzumab — Antibody.